Chief Commercial Officer · Xenon Pharmaceuticals Inc. (XENE)

Von Seggern Christopher

FY2024 is the first fiscal year CompBrief holds for Von Seggern Christopher as a named executive officer of Xenon Pharmaceuticals; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$4,090,590

Salary $480,000Stock awards $332,775

5th of 5 named executive officers at Xenon Pharmaceuticals by FY2024 total.

5 named officers on file for Xenon Pharmaceuticals, FY2024

Von Seggern Christopher’s pay file — $29

  • 1 fiscal year of pay, line by line
  • XENE’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Xenon Pharmaceuticals’s whole pay program stands against its peers

  • Xenon Pharmaceuticals’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on XENE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A).

Free

Get Von Seggern Christopher’s full pay file as a PDF — free

More than this page: up to 10 years of Von’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Von Seggern Christopher compensation by year

Xenon Pharmaceuticals Summary Compensation Table · the one fiscal year held
In US dollars, as Xenon Pharmaceuticals reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2024
Salary$480,000
Bonus$0
Stock awards$332,775
Option awards$3,089,463
Non-equity incentive$163,200
Pension and deferred compensation$0
All other$25,152
Total$4,090,590

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Xenon Pharmaceuticals Inc. DEF 14A filed April 24, 2025, accession 0000950170-25-058086, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Xenon Pharmaceuticals Inc. filed document, accession 0000950170-25-058086. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

Xenon Pharmaceuticals’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Ian MortimerPresident and Chief Executive Officer$9,795,347
Christopher KenneyChief Medical Officer$4,196,940
Sherry AulinChief Financial Officer$4,164,888
Andrea DiFabioChief Legal Officer and Corporate Secretary$4,104,490
Von Seggern Christopher · this pageChief Commercial Officer$4,090,590

The full Xenon Pharmaceuticals compensation record

free company brief

This page is one person within Xenon Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Xenon Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Von Seggern Christopher's compensation dossier · One-time report. No refunds.